logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
J

John Crown

School of Biotechnology

88H-index
865Paper Count
4.0WCitation Count
Published Papers 288
Publication Date
logo
Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer
errnpj Breast Cancer
IF7.6
err2026-08-05
err0
errOAAI
errAmira F. Mahdi; Myra Castel; Neil T. Conlon; Debbie O’Reilly; Niall Ashfield; Alexander Caffrey; Ailish Carey; Neil A. O’Brien; Enrique Guandique; Georg F. Bischof; John Crown; Denis M. Collins
errShare
errSave
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients
errOncogene
IF7.3
err2025-12-20
err0
errOAAI
errCharlotte Andrieu; Jojanneke Stoof; Dalal AlSultan; Laura Ivers; Jose Javier Berenguer Pina; Darko Skrobo; Jo Ballot; Debbie O’Reilly; Denis M. Collins; Alex J. Eustace; Cecily Quinn; Janice M. Walshe; Giuseppe Gullo; Naomi Walsh; John Crown
errShare
errSave
Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation
errMOLECULAR ONCOLOGY
IF4.5
err2025-11-01
err0
errOAAI
errCuy Saques, Arnau; Martinez-mendez, Aracele; Crown, John; Eustace, Alex
errShare
errSave
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆
errESMO Open
IF8.3
err2025-10-17
err0
errOAAI
errJ. Crown; D. Stroyakovskii; D.A. Yardley; C.-S. Huang; P.A. Fasching; A. Bardia; S. Chia; S.-A. Im; M. Martin; B. Xu; C.H. Barrios; M. Untch; R. Moroose; S.A. Hurvitz; G.N. Hortobagyi; D.J. Slamon; F. Visco; G. Spera; J.P. Zarate; D. Halligan; Z. Li; S. Loi
errShare
errSave
Spontaneous regression of metastatic disease after palliative debulking surgery for heavily pre-treated extraskeletal myxoid chondrosarcoma: A case report
errRARE TUMORS
IF0
err2025-10-01
err0
PREAI
errCarroll, Hailey Kathryn; Keogh, Anna; Barry, Simon; Fabre, Aurelie; O'toole, Gary; Crown, John; O'mahony, Deirdre; Feeley, Kenneth; Muneer, Asif; Bambury, Richard M.
errShare
errSave
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials
errONCOLOGIST
IF4.2
err2025-09-01
err0
errOAAI
errBlasco, Andrea; Lopez-Tarruella, Sara; Urruticoechea, Ander; Carrasco, Eva; Spera, Gonzalo; Martin, Miguel; Bermejo, Begona; Chap, Linnea; Ruiz-Borrego, Manuel; Crown, John; Garcia-Saenz, Jose A.; Chan, Arlene; Guerrero-Zotano, Angel; Semiglazov, Vladimir; Calvo, Lourdes; Pienkowski, Tadeusz; Herranz, Jesus; Slamon, Dennis
errShare
errSave
MYC as a Target for Cancer Treatment: from Undruggable to Druggable?
errTargeted Oncology
IF4
err2025-08-15
err0
errOAAI
errMichael J. Duffy; Minhong Tang; John Crown
errShare
errSave
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
errINTERNATIONAL JOURNAL OF CANCER
IF4.7
err2025-04-10
err0
errOAAI
errGarcia-Saenz, Jose A.; Spera, Gonzalo; Pollan, Marina; Bermejo, Begona; Ruiz-Borrego, Manuel; Chan, Arlene; Martin, Miguel; Guerrero-Zotano, Angel; Calvo, Lourdes; Rodriguez-Lescure, Alvaro; Marin, Maria; Chap, Linnea; Crown, John; Pienkowski, Tadeusz; Bee, Valerie; Casas, Maribel; Polonio, Oscar; Bezares, Susana; Slamon, Dennis
errShare
errSave
Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
errMOLECULAR CANCER
IF33.9
err2025-01-31
err0
errOAAI
errCorcoran, Claire; Rani, Sweta; Breslin, Susan; Gogarty, Martina; Ghobrial, Irene M.; Crown, John
errShare
errSave
Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630
errINVESTIGATIONAL NEW DRUGS
IF2.7
err2025-01-28
err0
errOAAI
errTang, Minhong; Crown, John; Duffy, Michael J.
errShare
errSave
Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer
errINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
IF4.9
err2025-01-08
err0
errOAAI
errMahdi, Amira F.; Ashfield, Niall; Crown, John; Collins, Denis M.
errShare
errSave
Safety, tolerability and blood pressure lowering of the innovative guanylyl cyclase a-receptor activator MANP in an ethnically diverse resistant hypertension population: a phase 1B clinical trial
errEUROPEAN HEART JOURNAL
IF35.6
err2024-10-28
err0
PREAI
errChen, H.; Smith, D. H.; Neutel, J. M.; Moroni, D.; Iyer, S. R.; Crown, J.; Sangaralingham, S. J.; Burnett, J. C.
errShare
errSave
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
errBREAST CANCER RESEARCH AND TREATMENT
IF3
err2024-10-04
err0
errOAAI
errBrowne, I. M.; McLaughlin, R. A.; Weadick, C. S.; O'Sullivan, S.; McSorley, L. M.; Hadi, D. K.; Millen, S. J.; Higgins, M. J.; Crown, J. P.; Prichard, R. S.; McCartan, D. P.; Hill, A. DK.; Connolly, R. M.; Noonan, S. A.; O'Mahony, D.; Murray, C.; O'Hanlon-Brown, C.; Hennessy, B. T.; Quinn, C. M.; Kelly, C. M.; O'Reilly, S.; Morris, P. G.; Walshe, J. M.
errShare
errSave
A RARE CASE OF NODULAR LUNG DISEASE ON A BACKGROUND OF LYMPHOMA
errCHEST
IF8.6
err2024-10-01
err0
PREAI
errLee, Amanda; O'Flaherty, Niamh; Murphy, David; Fabre, Aurelie; Crown, John; Garvey, John F.
errShare
errSave
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
errMOLECULAR CANCER
IF33.9
err2024-10-01
err0
errOAAI
errCorcoran, Claire; Rani, Sweta; Breslin, Susan; Gogarty, Martina; Ghobrial, Irene M.; Crown, John; O'Driscoll, Lorraine
errShare
errSave
Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) plus cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errMckean, M.; Weise, A. M.; Papadopoulos, K. P.; Crown, J. P.; Thomas, S. S.; Mehnert, J. M.; Kaczmar, J.; Kim, K. B.; Lakhani, N. J.; Yushak, M. L.; Mani, J.; Fang, F.; Brennan, L.; Lowy, I.; Salvati, M. E.; Fury, M. G.; Lewis, K.; Hamid, O.
errShare
errSave
Efficacy and safety of ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2-early breast cancer (EBC) in NATALEE
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err1
PREAI
errUntch, M.; Yardley, D.; Im, S-A.; Pluard, T.; Hart, L.; Crown, J. P.; Freyer, G.; Zamagni, C.; Lopez-Barajas, I. Blancas; Parnizari, F.; Gao, M.; Amin, K.; Hu, H.; Rugo, H. S.
errShare
errSave
SPATIAL IMMUNE CELL DISTRIBUTION CAN REFINE PROGNOSIS IN EARLY-STAGE ER+/HER2-/LN- BREAST CANCER
errCANCER RESEARCH
IF16.6
err2024-05-02
err0
PREAI
errKinsella, Zak; Nyarko, Hannah; Blumel, Anna; Lucas, Mairi; Kalinska-Lysiak, Daria; Gonzalez, Claudia Aura; Rahman, Arman; Fay, Joanna; O'Grady, Tony; Murphy, Verena; Crown, John; Kelly, Cathy; Gallagher, William; O'Connor, Darran
errShare
errSave
Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
errCANCER RESEARCH
IF16.6
err2024-05-02
err0
PREAI
errBrowne, Iseult; McLaughlin, Ronan; Weadick, Catherine; O'Sullivan, Shane; Millen, Steve; Hadi, Danial; Bilal-Shah, Syed; Al Sendhi, Maha; Higgins, Michaela; Crown, John; Prichard, Ruth; McCartan, Damian; Hill, Arnold; Connolly, Roisin; Noonan, Sinead; O'Mahony, Deirdre; O'Hanlon-Brown, Ciara; Hennessy, Bryan; Quinn, Cecily; Kelly, Catherine M.; O'Reilly, Seamus; Morris, Patrick G.; Walshe, Janice
errShare
errSave
Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
errCANCER RESEARCH
IF16.6
err2024-05-02
err3
PREAI
errHortobagyi, Gabriel; Stroyakovsky, Daniil; Yardley, Denise; Huang, Chiun-Shen; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Parnizari, Federico; Ghaznawi, Farhat; Li, Zheng; Waters, Sorcha; Chakravartty, Arunava; Slamon, Dennis
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
G
Gabriel N. Hortobágyi
H-index: 187 · Papers: 1.9K
C
Carlos Caldas
H-index: 158 · Papers: 1.4K
G
Giuseppe Viale
H-index: 157 · Papers: 1.3K
M
Martine Piccart
H-index: 149 · Papers: 1.6K
N
Norman Wolmark
H-index: 143 · Papers: 827
View more